Physicians' Academy for Cardiovascular Education

Lipids

Effects of a guideline-based approach on achieving LDL-c goals

3' education - Nov. 14, 2022 - Aaram Omar Khader, MD

Low-dose statin lowers LDL-c more than dietary supplements

3' education - Nov. 8, 2022 - Luke J. Laffin, MD

Effects of intensive lipid lowering on coronary plaque characteristics

10' education - Oct. 24, 2022 - Prof. Lorenz Räber, MD, PhD & Prof. Stephen Nicholls, MD

Targeting Lp(a): therapeutic insights and novel developments

10' education - Oct. 12, 2022 - Prof. Erik Stroes, MD, PhD

Real world evidence with PCSK9i mAb; implications and lessons for current clinical use

10' education - Oct. 12, 2022 - Raul Santos, MD, PhD & Prof. Maciej Banach, MD, PhD

Lp(a) as independent causal risk factor: why should we focus on testing?

10' education - Oct. 11, 2022 - Prof. Florian Kronenberg, MD, PhD

Targeting Lp(a) in CV risk reduction: where are we now?

10' education - Oct. 5, 2022 - Pia Kamstrup, MD, PhD

Sex-specific differences in the effects of LDL-c on CVD risk

5' education - Oct. 5, 2022 - Arjen Cupido, MD

LDL-c lowering with CETP inhibitor in patients on high intensity statins

10' education - Oct. 3, 2022 - Prof. Kausik Ray, MD

What have we learned from previous CETP inhibitor outcome trials?

10' education - Sep. 15, 2022 - Prof. Stephen Nicholls, MD

Meta-analysis on effects of statins on muscle symptoms

3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD

Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?

10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD

Optimizing treatment for patients with HoFH

10' education - July 13, 2022 - Prof. Erik Stroes, MD, PhD

HoFH: Why is early diagnosis important?

10' education - June 29, 2022 - Prof. Kausik Ray, MD

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD

Targeting the ANGPTL3 pathway for lowering TG-rich lipoproteins

3' education - May 24, 2022 - Nicholas Marston, MD

Lipid management and the potential role of bempedoic acid

10' education - Apr. 26, 2022 - Rens Reeskamp, MD, PhD

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD

Residual CV risk in patients on statin therapy

10' education - Apr. 13, 2022 - Prof. Alberto Zambon, MD, PhD

Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies

3' education - Apr. 6, 2022 - Brian Bergmark, MD

PCSK9i reduces plaque burden in coronary arteries

3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD

Working towards eradication of CV risk

10' education - Dec. 15, 2021 - Prof. Erik Stroes, MD, PhD

Lp(a) as therapeutic target - now and in the future

10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD - Online CME

Understanding the increased CV risk of high Lp(a) levels

10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD - Online CME

Changing the paradigm on LDL-c-lowering in high CV risk patients

10' education - Sep. 7, 2021 - Prof. Kausik Ray, MD - Online CME

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD

A decade of innovation, guidelines, and paradigm shifts in LDL-c management

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

The goal of LDL-c management is to reduce long-term CVD risk. Statins form the foundation of lipid-lowering therapy, but more ammunition is needed to attain LDL-c goals in all patients. This series of 3 presentations discusses current and evolving therapeutic LDL-c lowering options.

E-learning CETP inhibitors: Past, present and future

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

What is the rationale for CETP inhibition? Does it have the potential to lower the risk of CHD in addition to high-intensity statin therapy? What have we learned from previous CETP inhibitor outcome trials? and what trials can we expect in the near future? In this series of three presentations, you will be provided with novel insights on CETP inhibition.

Effects of a guideline-based approach on achieving LDL-c goals

3' education - Nov. 14, 2022 - Aaram Omar Khader, MD
Aaram Omar Kader talks about the PENELOPE study, that investigated the effect of a guideline-based approach on achieving LDL-c goals in very high-risk ACS patients in the Netherlands.

Aaram Omar Kader talks about the PENELOPE study, that investigated the effect of a guideline-based approach on achieving LDL-c goals in very high-risk ACS patients in the Netherlands.

Low-dose statin lowers LDL-c more than dietary supplements

3' education - Nov. 8, 2022 - Luke J. Laffin, MD
**AHA 2022** An RCT showed that low-dose statin is superior in lowering LDL-c compared with placebo and 6 different dietary supplements. Moreover, dietary supplements did not significantly reduce LDL-c compared with placebo.

AHA 2022 An RCT showed that low-dose statin is superior in lowering LDL-c compared with placebo and 6 different dietary supplements. Moreover, dietary supplements did not significantly reduce LDL-c compared with placebo.

Effect of dietary supplements on LDL-c compared with low-dose statin and placebo

News - Nov. 7, 2022

AHA 2022 In individuals with an increased 10-year ASCVD risk, rosuvastatin 5 mg daily reduced LDL-c, TC, and TG more than fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice, or placebo. Moreover, no supplements reduced LDL-c significantly compared with placebo.

Pemafibrate lowers triglycerides, but not CV event rates

News - Nov. 5, 2022

AHA 2022 The PROMINENT trial showed that pemafibrate reduces TG, VLDL-c, remnant cholesterol and ApoCIII in patients with T2DM, mild-to-moderate hypertriglyceridemia and low HDL-c. However, it did not reduce CV outcomes.

Does intermittent fasting reduce LDL-c?

Literature - Oct. 31, 2022 - Bartholomew CL et al. - Eur Heart J Open. 2021

In an RCT with 71 participants, low-frequency intermittent fasting for 26 weeks did not alter LDL-c levels compared with an ad libitum diet. However, it did lower insulin resistance and the metabolic syndrome score.

LDL-c response to bempedoic acid using statin intensity categories

Literature - Oct. 31, 2022 - Ballantyne CM et al. - J Am Heart Assoc. 2022

In a post-hoc analysis of 4 RCTs, a ≥30% LDL-c reduction with bempedoic acid was seen in 25% of statin-treated patients and in more than half of statin-naïve patients. Factors associated with this reduction were also assessed.

PCSK9i does not negatively influence cognitive functioning in children with HeFH

Literature - Oct. 24, 2022 - Gaudet D, et al. - J Clin Lipidol. 2022

RCTs among adults with HeFH show that treatment with evolocumab does not lead to cognitive dysfunction. But does the same hold true for pediatric patients with HeFH? This post-hoc analysis of data from the HAUSER-RCT study offers more insight.

Effects of intensive lipid lowering on coronary plaque characteristics

10' education - Oct. 24, 2022 - Prof. Lorenz Räber, MD, PhD & Prof. Stephen Nicholls, MD
Prof. Räber and Prof. Nicholls discuss the results and implications of the PACMAN-AMI study, that investigated the effect of PCSK9i alirocumab on top of high-intensity statins on coronary plaque characteristics in patients with acute MI.

Prof. Räber and Prof. Nicholls discuss the results and implications of the PACMAN-AMI study, that investigated the effect of PCSK9i alirocumab on top of high-intensity statins on coronary plaque characteristics in patients with acute MI.

Targeting Lp(a): therapeutic insights and novel developments

10' education - Oct. 12, 2022 - Prof. Erik Stroes, MD, PhD
The importance of measuring Lp(a) has been established. The next big question is: will we be able to attenuate Lp(a)-associated risk?

The importance of measuring Lp(a) has been established. The next big question is: will we be able to attenuate Lp(a)-associated risk?

Real world evidence with PCSK9i mAb; implications and lessons for current clinical use

10' education - Oct. 12, 2022 - Raul Santos, MD, PhD & Prof. Maciej Banach, MD, PhD
Raul Santos and Maciej Banach talk about the safety of PCSK9 mAbs and of very low cholesterol levels, and discuss the importance of patient education to improve adherence.

Raul Santos and Maciej Banach talk about the safety of PCSK9 mAbs and of very low cholesterol levels, and discuss the importance of patient education to improve adherence.